The role of ranitidine in the prevention of weight gai

Not Applicable

• Conditions: Condition 1: obesity. Condition 2: Schizophrenia. Condition 3: Schizoaffective disorders.; Drug-induced obesity; Schizophrenia; Schizoaffective disorders

• Registration Number: IRCT201009112181N5
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Taking olanzapine for thought disorder, Hospitalization for over 16 weeks, signing informed written consent
Exclusion criteria: The physical co-morbidity, Simultaneous taking of drugs with weight gain side effect, Special diets

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Body weight. Timepoint: Before and 16 weeks after intervention. Method of measurement: Weight Scale(kg).

Secondary Outcome Measures

Name	Time	Method
Ranitidine side effects. Timepoint: Weekly. Method of measurement: drugs side effects questionnaire.